Securities Registration: Employee Benefit Plan (s-8)
18 Março 2022 - 05:32PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 18,
2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
Registration Statement UNDER THE
SECURITIES ACT OF 1933
Oncternal Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
62-1715807
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
12230 El Camino Real, Suite 300
San Diego, California 92130
(858) 434-1113
(Address of Principal Executive Offices)
Oncternal Therapeutics, Inc. 2019 Incentive Award Plan
Oncternal Therapeutics, Inc. 2021 Employment Inducement
Award Plan
(Full Title of the Plans)
James B. Breitmeyer, M.D., Ph.D.
President and Chief Executive Officer
Oncternal Therapeutics, Inc.
12230 El Camino Real, Suite 300
San Diego, California 92130
(858) 434-1113
(Name, Address and Telephone Number, Including Area Code, of Agent
for Service)
Copy to:
Chase C. Leavitt
General Counsel & Secretary
Oncternal Therapeutics, Inc.
12230 El Camino Real, Suite 300
San Diego, California 92130
(858) 434-1113
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer or
a smaller reporting company or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities
Act. ☐
EXPLANATORY NOTE
This registration statement registers the offer and sale of an
additional 7,500,000 shares of common stock of Oncternal
Therapeutics, Inc. (the “Company”) for issuance under the 2019
Plan, and an additional 2,050,000 shares of common stock of the
Company for issuance under the Inducement Plan. In
accordance with Instruction E to Form S-8, the contents of
previously filed Form S-8 registration statement Nos. 333-254581
and 333-233288 relating to shares of common stock issuable pursuant
to the 2019 Plan and Inducement Plan are hereby incorporated herein
by reference.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I
of Form S-8 will be sent or given to participants as specified by
Rule 428(b)(1) of the Securities Act. These documents and the
documents incorporated by reference into this registration
statement pursuant to Item 3 of Part II of this
registration statement, taken together, constitute a prospectus
that meets the requirements of Section 10(a) of the Securities
Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
In this
registration statement, Oncternal Therapeutics, Inc. is sometimes
referred to as the “Company,” “registrant,” “we,” “us” or
“our.”
Item 3. Incorporation of Documents by Reference.
The Securities and Exchange Commission (“SEC”) allows us to
“incorporate by reference” the information we file with them, which
means that we can disclose important information to you by
referring you to those documents. The information
incorporated by reference is considered to be part of this
registration statement, and later information filed with the SEC
will update and supersede this information. We hereby
incorporate by reference into this registration statement the
following documents previously filed with the SEC:
|
(a)
|
the
Company’s
Annual
Report on Form 10-K for the fiscal year ended December 31,
2021, filed by the registrant with the SEC on March 10,
2022, and
|
|
(b)
|
the description of the registrant’s
common stock set forth in our
Registration
Statement on Form 8-A,
filed with the SEC on January 13, 2004, and any amendment or report
filed with the SEC for the purpose of updating such
description.
|
All reports and other documents filed by the Registrant pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), after the date of this
registration statement and prior to the filing of a post-effective
amendment which indicates that all securities offered hereby have
been sold or which deregisters all securities then remaining unsold
shall be deemed to be incorporated by reference into this
registration statement and to be a part hereof from the date of
filing of such documents. The Registrant expressly excludes from
such incorporation any information furnished pursuant to Item 2.02
or Item 7.01 of any Current Report on Form 8-K. Any document or any
statement contained in a document incorporated or deemed to be
incorporated herein by reference shall be deemed to be modified or
superseded for purposes of this registration statement to the
extent that a subsequently filed document or a statement contained
herein or in any other subsequently filed document which also is or
is deemed to be incorporated herein by reference modifies or
supersedes such document or such statement. Any such document or
statement so modified or superseded shall not be deemed, except as
so modified or superseded, to constitute a part of this
registration statement.
Item 8. Exhibits.
Exhibit
|
|
|
|
Incorporation by Reference
|
Number
|
|
Exhibit Description
|
|
Form
|
|
File no.
|
|
Exhibit No.
|
|
Filing Date
|
|
|
|
|
|
|
|
|
|
|
|
3.1
|
|
Restated Certificate of
Incorporation of the Registrant dated February 6, 2004 (“Restated
Certificate”)
|
|
S-3
|
|
333-127175
|
|
4.1
|
|
4-Aug-05
|
|
|
|
|
|
|
|
|
|
|
|
3.1.1
|
|
Certificate of Amendment
of Restated Certificate dated May 6, 2011
|
|
8-K
|
|
000-50549
|
|
3.2
|
|
6-May-11
|
|
|
|
|
|
|
|
|
|
|
|
3.1.2
|
|
Certificate of Amendment
of Restated Certificate dated May 6, 2014
|
|
8-K
|
|
000-50549
|
|
3.3
|
|
9-May-14
|
|
|
|
|
|
|
|
|
|
|
|
3.1.3
|
|
Certificate of Amendment
of Restated Certificate dated May 6, 2015
|
|
10-Q
|
|
000-50549
|
|
3.4
|
|
11-May-15
|
|
|
|
|
|
|
|
|
|
|
|
3.1.4
|
|
Certificate of Amendment
of Restated Certificate dated December 5, 2016
|
|
8-K
|
|
000-50549
|
|
3.1
|
|
5-Dec-16
|
|
|
|
|
|
|
|
|
|
|
|
3.1.5
|
|
Certificate of Amendment
of Restated Certificate dated June 7, 2019 related to the Reverse
Stock Split of the Registrant
|
|
8-K
|
|
000-50549
|
|
3.1
|
|
10-Jun-19
|
|
|
|
|
|
|
|
|
|
|
|
3.1.6
|
|
Certificate of Amendment
of Restated Certificate dated June 7, 2019 related to the Name
Change of the Registrant
|
|
8-K
|
|
000-50549
|
|
3.2
|
|
10-Jun-19
|
|
|
|
|
|
|
|
|
|
|
|
3.1.7
|
|
Certificate of Amendment
of Restated Certificate dated May 25, 2021
|
|
8-K
|
|
000-50549
|
|
3.1
|
|
28-May-21
|
|
|
|
|
|
|
|
|
|
|
|
3.2
|
|
Amended and Restated
Bylaws of the Registrant
|
|
8-K
|
|
000-50549
|
|
3.3
|
|
10-Jun-19
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
Specimen of Common Stock
Certificate
|
|
10-Q
|
|
000-50549
|
|
4.2
|
|
9-Aug-19
|
|
|
|
|
|
|
|
|
|
|
|
4.2
|
|
Form of Common Stock
Warrant, issued by Registrant pursuant to the Purchase Agreement
dated September 25, 2017, between Registrant and the purchasers
identified in Exhibit A therein
|
|
S-3
|
|
333-221040
|
|
4.9
|
|
20-Oct-17
|
|
|
|
|
|
|
|
|
|
|
|
4.3
|
|
Form of Warrant to
purchase shares of Series B-2 Preferred Stock of
Registrant
|
|
S-4
|
|
333-230758
|
|
4.11
|
|
8-Apr-19
|
|
|
|
|
|
|
|
|
|
|
|
4.3.1
|
|
Form of Amendment to
Warrant to Purchase shares of Series B-2 Preferred Stock of Private
Oncternal
|
|
10-Q
|
|
000-50549
|
|
4.1
|
|
9-Aug-19
|
|
|
|
|
|
|
|
|
|
|
|
4.4
|
|
Form of Common Stock
Warrant, issued by Registrant pursuant to the Securities Purchase
Agreement dated May 19, 2020, between the Registrant and the
purchasers signatory thereto (“May 2020 Purchase
Agreement”)
|
|
8-K
|
|
000-50549
|
|
4.1
|
|
21-May-20
|
|
|
|
|
|
|
|
|
|
|
|
4.5
|
|
Form of Placement Agent
Warrant, issued by Registrant pursuant to the May 2020 Purchase
Agreement
|
|
8-K
|
|
000-50549
|
|
4.2
|
|
21-May-20
|
|
|
|
|
|
|
|
|
|
|
|
4.6
|
|
Form of Common Stock
Warrant, issued by Registrant pursuant to the Securities Purchase
Agreement dated July 17, 2020, between the Registrant and the
purchasers signatory thereto (the “July 2020 Purchase
Agreement”)
|
|
8-K
|
|
000-50549
|
|
4.1
|
|
21-Jul-20
|
|
|
|
|
|
|
|
|
|
|
|
4.7
|
|
Form of Placement Agent
Warrant, issued by Registrant pursuant to the July 2020 Purchase
Agreement.
|
|
8-K
|
|
000-50549
|
|
4.2
|
|
21-Jul-20
|
|
|
|
|
|
|
|
|
|
|
|
4.8
|
|
Form of Underwriter
Warrant, issued by Registrant pursuant to the Amended and Restated
Underwriting Agreement dated August 27, 2020, between the
Registrant and H.C. Wainwright & Co., LLC (“H.C.
Wainright”)
|
|
8-K
|
|
000-50549
|
|
4.1
|
|
31-Aug-20
|
|
|
|
|
|
|
|
|
|
|
|
4.9
|
|
Form of Underwriter
Warrant, issued by Registrant pursuant to the Amended and Restated
Underwriting Agreement dated November 17, 2020, between the
Registrant and H.C. Wainwright
|
|
8-K
|
|
000-50549
|
|
4.1
|
|
19-Nov-20
|
|
|
|
|
|
|
|
|
|
|
|
4.10
|
|
Form of Underwriter
Warrant, issued by Registrant pursuant to the Amended and Restated
Underwriting Agreement dated December 9, 2020, between the
Registrant and H.C. Wainwright
|
|
8-K
|
|
000-50549
|
|
4.1
|
|
11-Dec-20
|
|
|
|
|
|
|
|
|
|
|
|
4.11
|
|
Description of Securities
of the Registrant
|
|
10-K
|
|
000-50549
|
|
4.11
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
5.1*
|
|
Opinion of Counsel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1
|
|
2019 Incentive Award Plan
of the Registrant effective June 7, 2019 (the “2019
Plan”)
|
|
10-K
|
|
000-50549
|
|
10.18
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.1
|
|
Form of Stock Option
Agreement under the 2019 Plan
|
|
10-K
|
|
000-50549
|
|
10.18.1
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.1.2
|
|
Form of Restricted Stock
Unit under the 2019 Plan
|
|
10-K
|
|
000-50549
|
|
10.18.2
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2
|
|
2021 Employment Inducement
Incentive Award Plan of the Registrant (the “Inducement
Plan”)
|
|
8-K
|
|
000-50549
|
|
10.1
|
|
17-Feb-21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2.1#
|
|
Form of Stock Option under
the Inducement Plan
|
|
10-K
|
|
000-50549
|
|
10.19.1
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2.2#
|
|
Amendment No. 1 to the
Inducement Plan dated May 25, 2021
|
|
8-K
|
|
000-50549
|
|
10.1
|
|
25-May-21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2.3#
|
|
Amendment No. 2 to the
Inducement Plan dated December 15, 2021
|
|
10-K
|
|
000-50549
|
|
10.19.3
|
|
10-Mar-22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1*
|
|
Consent of BDO USA
LLP, Independent Registered Public Accounting
Firm
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.2*
|
|
Consent of Counsel (included in
Exhibit 5.1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1*
|
|
Power of Attorney (included in the signature page to this
Registration Statement)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
107*
|
|
Filing Fee Table
|
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant
certifies that it has reasonable grounds to believe that the
registrant meets all of the requirements for filing on
Form S-8 and has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized,
in the City of San Diego, State of California, on March 18,
2022.
oncternal therapeutics, Inc.
|
|
|
|
By:
|
|
/s/James B. Breitmeyer, M.D., Ph.D.
|
|
|
James B. Breitmeyer, M.D., Ph.D.
|
|
|
President and Chief Executive Officer
|
Each person whose signature appears below hereby constitutes and
appoints James B. Breitmeyer, M.D., Ph. D. and Richard G. Vincent,
and each of them, his or her true and lawful attorneys-in-fact and
agents, each with full power of substitution and resubstitution,
for him or her and in his name, place and stead, in any and all
capacities, to sign any and all amendments, including
post-effective amendments, to this Registration Statement, and any
registration statement relating to the offering covered by this
Registration Statement and filed pursuant to Rule 462(b) under the
Securities Act of 1933, and to file the same, with exhibits thereto
and other documents in connection therewith, with the Securities
and Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to be
done, as fully to all intents and purposes as he or she might or
could do in person, hereby ratifying and confirming all that each
of said attorneys-in-fact and agents or their substitute or
substitutes may lawfully do or cause to be done by virtue
hereof.
Pursuant
to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been
signed by the following persons in the capacities and on the dates
indicated.
Signature
|
Title
|
Date
|
|
|
|
/s/ James B. Breitmeyer, M.D., Ph.D.
James B. Breitmeyer, M.D., Ph.D.
|
President and Chief Executive Officer and Director
(Principal Executive
Officer)
|
March 18, 2022
|
|
|
|
/s/ Richard G. Vincent
Richard G. Vincent
|
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
|
March 18, 2022
|
|
|
|
/s/ David F. Hale
David F. Hale
|
Chairman of the Board of Directors
|
March 18, 2022
|
|
|
|
/s/ Michael G. Carter, M.B., ChB., F.R.C.P.
Michael G. Carter, M.B., ChB., F.R.C.P.
|
Director
|
March 18, 2022
|
|
|
|
/s/ Daniel L. Kisner, M.D.
Daniel L. Kisner, M.D.
|
Director
|
March 18, 2022
|
|
|
|
/s/ William R. LaRue
William R. LaRue
|
Director
|
March 18, 2022
|
|
|
|
/s/ Rosemary Mazanet, M.D., Ph.D.
Rosemary Mazanet, M.D., Ph.D.
|
Director
|
March 18, 2022
|
|
|
|
Xin Nakanishi, Ph.D.
|
Director
|
|
|
|
|
/s/ Charles P. Theuer, M.D., Ph.D.
Charles P. Theuer, M.D., Ph.D.
|
Director
|
March 18, 2022
|
|
|
|
Jinzhu Chen, Ph.D.
|
Director
|
|
|
|
|
/s/ Robert J. Wills, Ph.D.
Robert J. Wills, Ph.D.
|
Director
|
March 18, 2022
|
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022